Amalgamated Bank Sells 789 Shares of Humana Inc. (NYSE:HUM)

Amalgamated Bank decreased its position in Humana Inc. (NYSE:HUM) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,562 shares of the insurance provider’s stock after selling 789 shares during the quarter. Amalgamated Bank’s holdings in Humana were worth $5,978,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. AMF Tjanstepension AB boosted its stake in shares of Humana by 166.8% in the 3rd quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock valued at $12,686,000 after purchasing an additional 25,041 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Humana by 12.7% in the third quarter. Assenagon Asset Management S.A. now owns 4,090 shares of the insurance provider’s stock worth $1,295,000 after purchasing an additional 461 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its position in Humana by 7.4% during the third quarter. DekaBank Deutsche Girozentrale now owns 55,702 shares of the insurance provider’s stock valued at $17,652,000 after buying an additional 3,862 shares during the period. Your Advocates Ltd. LLP boosted its position in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the period. Finally, AustralianSuper Pty Ltd grew its stake in shares of Humana by 35.2% during the third quarter. AustralianSuper Pty Ltd now owns 2,495 shares of the insurance provider’s stock valued at $790,000 after buying an additional 650 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

HUM has been the subject of a number of recent research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Barclays boosted their price objective on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Royal Bank of Canada restated an “outperform” rating and issued a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. JPMorgan Chase & Co. lowered their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Finally, Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and increased their price target for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Nineteen research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Humana has a consensus rating of “Hold” and a consensus price target of $285.68.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Humana Stock Down 1.6 %

Shares of NYSE:HUM opened at $255.06 on Thursday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The firm has a market capitalization of $30.77 billion, a P/E ratio of 25.63, a P/E/G ratio of 2.05 and a beta of 0.56. The stock has a 50 day moving average price of $270.12 and a 200-day moving average price of $288.06.

Humana (NYSE:HUM) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.39%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s payout ratio is currently 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.